Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204083 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5737318 | 0.91 | TAS1R3 (0.51) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5063703 | 0.90 | TAS1R3 (0.48) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL7402512 | 0.90 | MCHR1 (0.52) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL7402511 | 0.90 | MCHR1 (0.52) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5733789 | 0.88 | ALDH1A1 (0.52) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5733889 | 0.88 | TACR1 (0.51) | TAS1R3TAS1R1MEN1KMT2APDE4A | |
| SCHEMBL5733787 | 0.88 | ALDH1A1 (0.52) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5734634 | 0.88 | TAS1R3 (0.48) | TAS1R3TAS1R1MEN1KMT2AALPL | |
| SCHEMBL5734639 | 0.88 | TAS1R3 (0.48) | TAS1R3TAS1R1MEN1KMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214536-A1 | Amido-Substituted 6-Phenylphenanthridines | NYCOMED GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1858880-A1 | AMIDO-SUBSTITUTED 6-PHENYLPHENANTHRIDINES | Nycomed GmbH (DE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006095009-A1 | AMIDO-SUBSTITUTED 6-PHENYLPHENANTHRIDINES | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060116518-A1 | Novel phenanthridines | ALTANA PHARMA AG (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-1537086-A2 | NOVEL PHENANTHRIDINES | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004018431-A2 | NOVEL PHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-0882021-B1 | NEW PHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002006239-A1 | PHENANTHRIDINE N-OXIDES | ALTANA PHARMA AG (DE) | 2002-01-24 | — | — | WO | disclosed |
| US-6191138-B1 | THERAPY FOR RESPIRATORY SYSTEM DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214536-A1 | Amido-Substituted 6-Phenylphenanthridines | PDE4A, PDE4B, PDE3A | TAS1R3 413/4885TAS1R1 503/4885MEN1 2731/4885 |
| US-20060116518-A1 | Novel phenanthridines | PDE4A, PDE4B, PDE3A | TAS1R3 1348/4885TAS1R1 1160/4885MEN1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.